Biotech is going to have a hard time until the end of rate cycle, says E Squared's Les Funtleyder Previous I'm not sure we know which health care companies will negotiate prices, says E Squared's Funtleyder Next Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
Biotech is going to have a hard time until the end of rate cycle, says E Squared's Les Funtleyder Previous I'm not sure we know which health care companies will negotiate prices, says E Squared's Funtleyder Next Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
